NCT00480090View on ClinicalTrials.gov

A Phase II Study of Ara-C (Cytarabine) in Men With Androgen Independent Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

October 31, 2010

Study Completion Date

July 31, 2011

Conditions
Prostate Cancer
Interventions
DRUG

Cytarabine

Initially given at 1g/m2 bid for 2 days every 3 weeks over 2 hours. The dose will be escalated: level 1 - 1.25g/m2, level 2, 1.5g/m2.

Trial Locations (1)

M5G 2M9

University Health Network, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT00480090 - A Phase II Study of Ara-C (Cytarabine) in Men With Androgen Independent Prostate Cancer | Biotech Hunter | Biotech Hunter